Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	16/NW/0056	184887	Outcomes Review of Patients Following Post-mastectomy Breast Reconstruction Using Implants with Strattice(TM) Reconstructive Tissue Matrix	Range Agreed	30	47	Date Agreed	31/10/2019	12	12	31/10/2019	Recruitment finished	The study was dependent on voluntary participation and numbers anticipated were very difficult to obtain for recruitment
2	17/NE/0148	226163	Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate, in Patients with CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma	Number Agreed	5	5	Date Agreed	30/11/2019	0	0	26/11/2019	Withdrawn by sponsor	The sponsor identified an MDT that proved impossible for the drug to be given without Neutropaenia. The study was closed for the safety of the patients
3	17/EM/0154	222192	A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment with PXT002331 (foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects with Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)	Range Agreed	3	10	Date Agreed	31/12/2019	10	10	23/12/2019	Recruitment finished	
4	18/NE/0052	234786	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients with C3 Glomerulopathy	Number Agreed	4	4	Date Agreed	30/11/2019	4	4	29/11/2019	Recruitment finished	
5	18/NW/0312	233643	A prospective, observational, UK study to describe the patient reported quality of life in relapsing remitting multiple sclerosis patients treated with Aubagio (teriflunomide) 14mg in a routine clinical practice	Range Agreed	2	5	Date Agreed	31/03/2020	2	2	11/11/2019	Recruitment finished	
6	17/EM/0371	229496	Strategic Management to Optimize Response To Cardiac Re synchronization Therapy SMART CRT	Range Agreed	1	5	Date Agreed	31/10/2019	1	1	25/10/2019	Recruitment finished	
7	17/YH/0392	230501	A randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 weeks with a 12 week follow up period in patients with non proliferative diabetic retinopathy without centre-involved diabetic macular edema.	Number Agreed	4	4	Date Agreed	31/10/2019	4	4	28/10/2019	Recruitment finished	
8	17/NE/0240	224762	A Multi-Center, Prospective, Pragmatic, Randomized, Controlled Clinical Trial to Compare HF10 Therapy to Conventional Medical Management in the Treatment of Non-Surgical Refractory Back Pain	Number Agreed	9	9	Date Agreed	31/12/2019	9	9	31/12/2019	Recruitment finished	
9	18/NW/0325	244842	A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients with Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy	Number Agreed	4	4	Date Agreed	31/12/2019	4	4	31/12/2019	Recruitment finished	
10	18/NE/0142	242919	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis	Number Agreed	4	4	Date Agreed	31/12/2019	3	3	31/12/2019	Recruitment finished	After screening many patients the time limits upheld by the sponsor meant the study had to close before we could recruit the fourth patient

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
11	18/SC/0421	247127	A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis	Number Agreed	4	4	Date Agreed	23/12/2019	4	4	23/12/2019	Recruitment finished	
12	18/LO/0416	235395	A Phase 1b/2 Study to Evaluate Safety and Anti-tumour Activity of Avelumab in Combination with the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Locally Advanced or Metastatic Solid Tumours.	Number Agreed	8	8	Date Agreed	15/11/2019	8	8	15/11/2019	Recruitment finished	
13	18/WS/0118	244998	A Prospective Clinical Study Evaluating the Safety and Haemostatic Effectiveness of SURGICEL®/TABOTAMP® Powder, Absorbable Haemostatic Powder (oxidized regenerated cellulose) in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding during General, Gynaecological, Urological and Cardiothoracic Surgery in Adult Patients	Range Agreed	12	20	Date Agreed	30/04/2020	19	19	09/12/2019	Recruitment finished	Sponsor announced that the Surgicel Power PMCF study had completed enrolment 6 months ahead of their projected enrolment end date
14	18/LO/2194	257040	IMCY-T1D-002 Long-term follow-up study of T1D patients	Number Agreed	2	2	Date Agreed	31/10/2019	2	2	08/10/2019	Recruitment finished	
15	17/EM/0241	223736	Safety and efficacy analysis of FRED™/FRED™ Jr embolic device in aneurysm treatment	Range Agreed	2	10	Date Agreed	31/12/2019	4	4	31/12/2019	Recruitment finished	
16	19/EM/0047	257111	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (TENAYA)	Number Agreed	5	5	Date Agreed	01/05/2020	5	5	23/10/2019	Recruitment finished	
17	18/EM/0366	253697	A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subjects with Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs	Number Agreed	1	1	Date Agreed	22/11/2019	0	0	31/10/2019	Withdrawn by sponsor	Recruitment was stopped nationally as the target was met early
18	18/LO/0144	239494	A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Study to Assess the Safety and Efficacy of Three Doses of Clobetasol Propionate when Administered Intra-orally Twice Daily in Patients with Oral Lichen Planus (OLP) using Rivelin®-CLO Patches	Number Agreed	12	12	Date Agreed	14/11/2019	1	1	11/11/2019	Withdrawn by sponsor	The Data Monitoring Committee's (DMC) recommendation was to stop enrollment on the study
19	18/WS/0201	251717	A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA)	Number Agreed	2	2	Date Agreed	30/11/2019	2	2	30/11/2019	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
20	16/LO/1082	207150	CC-90011-ST-001 (Celgene study)	Range Agreed	10	15	Date Agreed	03/12/2019	8	8	03/12/2019	Withdrawn by host	Team felt they would not recruit any more patients to the study as they rarely see the required mutation
21	17/NE/0176	219406	AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY	Number Agreed	6	6	Date Agreed	30/12/2019	6	6	30/12/2019	Recruitment finished	
22	16/SC/0200	202397	Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women with Preeclampsia via Apheresis Utilizing the Flt-1 Adsorption Column	Number Agreed	1	1	Date Agreed	31/10/2019	0	0	31/10/2019	Recruitment finished	The eligibility criteria was very strict for this study. Throughout the study we only had one woman who was eligible, however she was delivered before recruitment due to her condition
23	17/NW/0022	219189	Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases	Number Agreed	2	2	Date Agreed	10/01/2022	1	1	22/10/2019	Withdrawn by sponsor	Recruitment was closed early by the sponsor as the overall enrolment target was achieved globally
24	17/EE/0017	109044	A double-blind, placebo controlled, multicentre, clinical trial to investigate the efficacy and safety of 12 months of therapy with inhaled Promixin (colistimethate sodium) in the treatment of subjects with non-cystic fibrosis bronchiectasis chronically infected with Pseudomonas aeruginosa (P.aeruginosa)	Number Agreed	1	1	Date Agreed	08/10/2019	0	0	08/10/2019	Recruitment finished	The Inclusion criteria was tight and not study product at the end of the trial. The patients would have had to go back to their original medication and this was a barrier for recruitment. Only one patient met eligibility but they did not want to take part.
25	16/NE/0384	209045	A multi-center, randomized, double-blind, active-controlled, parallel group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in patients with left ventricular dysfunction following an acute myocardial infarction	Range Agreed	5	40	Date Agreed	31/03/2020	37	37	31/03/2020	Recruitment finished	
26	17/EM/0122	224376	A PHASE 3, OPEN-LABEL, MULTICENTER STUDY OF ALXN1210 IN CHILDREN AND ADOLESCENTS WITH ATYPICAL HEMOLYTIC-UREMIC SYNDROME (aHUS)	Number Agreed	1	1	Date Agreed	04/10/2020	0	0	06/02/2020	Withdrawn by sponsor	This is a rare disease study and no patient presented at Newcastle before the sponsor reached their target globally
27	16/LO/2126	218039	A randomized trial comparing the ELUVIA™ drug-eluting stent versus bare Metal self-expanding nitINol stEnts in the treatmeNt of superficial femoral and/or proximal popliteal arTeries	Range Agreed	5	10	Date Agreed	31/03/2020	5	5	31/03/2020	Recruitment finished	
28	17/WM/0308	226910	Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects with Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas aeruginosa (PA) Infection/Colonization	Range Agreed	0	1	Date Agreed	02/06/2021	0	0	16/01/2020	Withdrawn by sponsor	Sponsor reached the required number of evaluable subjects to power the primary analysis appropriately.
29	17/EM/0481	233652	A multicenter, prospective, observational cohort study to evaluate the real-world safety and effectiveness of Erelzi™, an etanercept biosimilar (COMPACT)	Range Agreed	10	30	Date Agreed	31/12/2019	14	14	31/12/2019	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
30	16/LO/2002	214578	A Double-Blind, Placebo-Controlled, Multicenter Study with an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients with Duchenne Muscular Dystrophy	Range Agreed	1	5	Date Agreed	21/07/2020	5	5	21/01/2020	Recruitment finished	
31	17/YH/0426	231118	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly with Topical Corticosteroids in Patients, =6 Years to <12 Years Of Age, with Severe Atopic Dermatitis	Number Agreed	3	3	Date Agreed	31/03/2020	0	0	31/03/2020	Withdrawn by sponsor	The study was halted early as the global target was reached ahead of time
32	18/NE/0194	242874	A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients with Type 2 Diabetes Post Worsening Heart Failure	Range Agreed	1	5	Date Agreed	31/10/2020	1	1	24/03/2020	Withdrawn by sponsor	Notification that the study had ended globally
33	18/NE/0309	252961	An Open-Label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment with Oral REN001 in Patients with Primary Mitochondrial Myopathy (PMM), with an Optional Extension of Treatment	Range Agreed	8	14	Date Agreed	15/01/2020	12	12	15/01/2020	Recruitment finished	
34	18/LO/1542	247189	A Phase 2, randomized, double-blind placebo-controlled study to test the efficacy and safety of KPL-301 in giant cell arteritis	Range Agreed	1	4	Date Agreed	14/02/2020	0	0	03/01/2020	Withdrawn by sponsor	Sponsor closed the study locally as recruitment was reached globally
35	19/EE/0124	260061	Investigation of efficacy and safety of semaglutide s.c. once-weekly versus placebo in subjects with non-alcoholic steatohepatitis and compensated liver cirrhosis	Range Agreed	1	2	Date Agreed	05/03/2020	1	1	04/03/2020	Recruitment finished	
36	19/NW/0482	269475	A Phase 3b, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del	Number Agreed	5	5	Date Agreed	31/12/2020	5	5	18/12/2019	Recruitment finished	
37	19/YH/0067	254066	A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab as first line therapy for locally advanced or metastatic non-squamous and squamous non-small cell lung cancer subjects (CANOPY-1)	Number Agreed	3	3	Date Agreed	21/10/2022	1	1	10/12/2019	Withdrawn by sponsor	Study closed early by sponsor
38	19/NI/0110	260538	EluNIR Ridaforolimus Eluting Coronary Stent System in patients at high bleeding risk (HBR)– EluNIR HBR study	Range Agreed	0	2	Date Agreed	01/09/2020	0	0	29/02/2020	Recruitment finished	Recruitment finished with no recruits however, sponsor had decided on a 0 to 2 target
39	19/LO/1035	264950	A Phase 3b, Multicenter, Interventional, Randomized, Placebo-controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar non-Pustular Psoriasis	Number Agreed	2	2	Date Agreed	31/07/2020	2	2	27/03/2020	Recruitment finished	
40	19/NE/0115	255707	An Open Label, Multi-Centre, 24 Week, Exploratory Study to Assess the Efficacy and Safety of Skilarence® (Dimethyl Fumarate) in Patients with Moderate Plaque Psoriasis	Range Agreed	3	10	Date Agreed	31/03/2020	10	10	23/03/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
41	19/HRA/7127	275934	Long term survival and healthcare resource use in patients with hepatic encephalopathy receiving rifaximin-α treatment: a retrospective observational extension study with long term follow-up (IMPRESS II)	Range Agreed	15	25	Date Agreed	29/02/2020	25	25	29/02/2020	Recruitment finished	
42	17/EE/0400	224645	A Multicenter, Randomized, Double-Blind,Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease	Range Agreed	3	6	Date Agreed	30/03/2020	3	3	30/03/2020	Recruitment finished	
43	16/NE/0147	204478	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis	Range Agreed	5	20	Date Agreed	31/05/2020	6	6	31/05/2020	Recruitment finished	
44	16/NE/0413	210215	Randomised, double blind, placebo controlled, multicentre study to evaluate the efficacy and safety of givinostat in ambulant patients with Duchenne Muscular Dystrophy.	Range Agreed	3	6	Date Agreed	01/06/2020	3	3	01/06/2020	Recruitment finished	
45	14/NE/1099	144103	Phase III, Randomized, Multicenter Double-Blind, Double Dummy Study To Evaluate The Efficacy And Safety Of Etrolizumab Compared With Infliximab In Patients With Moderate To Severe Active Ulcerative Colitis Who Are Naive To TNF Inhibitors	Range Agreed	4	10	Date Agreed	31/12/2021	7	7	14/04/2020	Recruitment finished	
46	17/EE/0401	224915	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	Range Agreed	1	3	Date Agreed	29/05/2020	2	2	29/05/2020	Recruitment finished	
47	17/YH/0391	229417	Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis	Range Agreed	2	5	Date Agreed	30/04/2020	3	3	30/04/2020	Recruitment finished	
48	18/LO/1925	250709	A PHASE II, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, DOUBLEDUMMY, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF UTTR1147A COMPARED WITH PLACEBO AND COMPARED WITH VEDOLIZUMAB IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	Range Agreed	0	1	Date Agreed	15/10/2020	0	0	01/05/2020	Withdrawn by sponsor	
49	18/LO/1927	242927	A PHASE II OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF UTTR1147A IN PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS OR CROHN'S DISEASE	Range Agreed	1	2	Date Agreed	31/10/2020	0	0	01/05/2020	Withdrawn by sponsor	Following USM to suspend follow up & Recruitment Protocol amendment adds management of COVID-19 patients as well as incorporating protocol clarification letters 1 & 2. This study is pending close out, no patients were recruited or planned to be recruited
50	19/SC/0148	260130	XTEND – evaluation of an eXtended and proactive dosing regimEn in treatment-Naïve patients with wet age related macular Degeneration (wAMD)	Number Agreed	30	30	Date Agreed	15/05/2020	30	30	28/04/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
51	18/SW/0214	249435	A Multinational, Prospective, Observational Study of the Effectiveness, Healthcare Resource Utilization and Costs in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic or Biologic Disease-Modifying Therapies	Number Agreed	10	10	Date Agreed	31/12/2024	11	11	20/04/2020	Recruitment finished	
52	19/NW/0540	269907	A Phase 3, Open-label Study Evaluating the Long-term Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis	Number Agreed	2	2	Date Agreed	31/03/2020	2	2	31/03/2020	Recruitment finished	
53	19/EM/0220	265213	A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed	Number Agreed	2	2	Date Agreed	21/05/2020	2	2	21/05/2020	Recruitment finished	
54	18/YH/0349	243300	Pyruvate Kinase Deficiency Global Longitudinal Registry	Range Agreed	2	5	Date Agreed	28/12/2024	3	3	06/04/2020	Recruitment finished	
55	18/SC/0240	230920	A Phase III, multicentre, randomised, double-blind, placebo-controlled, parallel-group, efficacy, and safety study of gantenerumab in patients with prodromal to mild Alzheimer's Disease	Range Agreed	2	4	Date Agreed	30/06/2020	2	2	19/06/2020	Recruitment finished	
56	18/SS/0144	248553	An open-label, non-investigational product, multi-centre, lead-in study to evaluate at least 6 months of prospective efficacy and selected safety data of factor IX (FIX) prophylaxis replacement therapy in the usual care setting of moderately severe to severe adult haemophilia B subjects (FIX:C≤2%) who are negative for neutralising antibodies (NAB) to adeno-associated virus vector (AAV)-spark100	Number Agreed	2	2	Date Agreed	30/05/2020	1	1	31/03/2020	Recruitment finished	Global recruitment was reached and the study closed to recruitment at Newcastle
57	17/SC/0345	225047	A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections	Number Agreed	2	2	Date Agreed	01/07/2020	1	1	01/07/2020	Recruitment finished	Study closed internationally before we were able to recruit more participants
58	17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	Range Agreed	1	2	Date Agreed	20/07/2020	2	2	01/07/2020	Recruitment finished	
59	18/SW/0049	237051	A Multicenter, Open-Label, Phase 1B/2 Study to Evaluate Safety and Efficacy of Avelumab (MSB0010718C) in Combination with Chemotherapy with or without Other Anti-Cancer Immunotherapies as First-Line Treatment in Patients with Advanced Malignancies	Number Agreed	4	4	Date Agreed	06/09/2020	4	4	12/08/2020	Recruitment finished	
60	18/EM/0005	236933	An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices	Number Agreed	5	5	Date Agreed	31/03/2021	5	5	10/08/2020	Recruitment finished	
61	17/SC/0491	228055	A Phase 1-2, Open-Label, Dose-Finding, Proof Of Concept, First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CX-2009 In Adults With Metastatic Or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)	Number Agreed	4	4	Date Agreed	31/05/2020	1	1	09/04/2020	Withdrawn by sponsor	CytomX decided to close Study CTMX-M-2009-001 to screening and enrollment, based an assessment of the continued challenges for clinical trial execution in the current COVID-19 pandemic environment and the ongoing demands the pandemic placed on the health care system

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
62	18/NE/0235	244048	A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)	Number Agreed	5	5	Date Agreed	31/08/2020	5	5	31/08/2020	Recruitment finished	
63	18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Number Agreed	3	3	Date Agreed	18/12/2020	5	5	21/08/2020	Recruitment finished	
64	18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	Range Agreed	2	5	Date Agreed	30/08/2020	0	0	02/07/2020	Withdrawn by sponsor	Complexa decided to terminate the study CXA-10-301 (PRIMEx) due to delays in recruitment of PRIMEx patients, creating a minimum 6 month delay due to COVID-19
65	18/LO/1859	252363	Observational cohort study of patients with hormone receptor-positive metastatic breast cancer treated with palbociclib (Ibrance®) as part of the United Kingdom Ibrance® Patient Program (IPP); the Real Outcomes Ibrance® Study (ROIS)	Range Agreed	7	13	Date Agreed	28/02/2021	10	10	03/08/2020	Recruitment finished	
66	19/NE/0076	242027	BIOTRONIKS - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV	Range Agreed	5	15	Date Agreed	31/10/2020	9	9	14/07/2020	Recruitment finished	
67	19/NW/0001	253853	IDL-2965 – A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis	Range Agreed	1	3	Date Agreed	30/06/2020	0	0	26/05/2020	Withdrawn by sponsor	Study was closed to recruitment nationally because of COVID-19
68	18/LO/1397	247266	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis	Range Agreed	2	4	Date Agreed	12/09/2020	0	0	04/09/2020	Withdrawn by sponsor	The sponsor took a decision to terminate the program
69	19/SC/0256	263749	A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult episodic migraine patients	Number Agreed	6	6	Date Agreed	09/10/2020	0	0	25/08/2020	Withdrawn by sponsor	In the UK we were slower to reactivate sites after the lockdown and other centers abroad recruited faster
70	19/EE/0135	252796	A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oral Topotecan with HM30181A Monotherapy in Patients with Advanced Malignancies	Range Agreed	6	16	Date Agreed	01/08/2020	1	1	15/06/2020	Withdrawn by sponsor	Sponsor closed recruitment unexpectedly early
71	19/NW/0504	264255	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy	Range Agreed	3	6	Date Agreed	31/10/2020	5	5	22/07/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments